Home›Eliglustat›Eliglustat + Mao Inhibitors

Does Eliglustat Interact with Mao Inhibitors?

CDI records a contraindicated classification for Eliglustat and Mao Inhibitors. The stored summary is: Strong CYP3A inhibitors are contraindicated in intermediate and poor CYP2D6 metabolizers due to increased eliglustat concentrations and cardiac arrhythmia risk. The mechanism involves inhibition of cyp3a metabolism of eliglustat. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.

Stored CDI classification
Contraindicated
Eliglustat Class
Glucosylceramide Synthase Inhibitor
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Inhibition of CYP3A metabolism of eliglustat

What To Tell Your Doctor or Pharmacist

If you are taking Eliglustat and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Eliglustat(Cerdelga)+💊 Mao Inhibitors

Severity & Interaction Details

⛔
contraindicated
Stored CDI classification: contraindicated
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
Glucosylceramide Synthase Inhibitor
Drug B class
—
Source
NLP:eliglustat

What this means in plain English

Strong CYP3A inhibitors are contraindicated in intermediate and poor CYP2D6 metabolizers due to increased eliglustat concentrations and cardiac arrhythmia risk.

About Eliglustat and Mao Inhibitors

Eliglustat is a Glucosylceramide Synthase Inhibitor. Eliglustat is also sold under the brand name Cerdelga.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:eliglustat

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Eliglustat and Mao Inhibitors against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations